Last reviewed · How we verify
NCT04759794: MARS1
Clinical Validation of an Immunocytochemistry Method Using MARS1
NA trial testing Cytology staining in Bile Duct Obstruction, Extrahepatic in 55 participants. Completed in 3 February 2023.
3 February 2023
Quick facts
| Lead sponsor | Gangnam Severance Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 55 |
| Start date | 4 February 2021 |
| Primary completion | 3 February 2023 |
| Estimated completion | 3 February 2023 |
| Sites | 5 locations across South Korea |
Drugs / interventions tested
- Cytology staining
Conditions studied
- Bile Duct Obstruction, Extrahepatic — all drugs for Bile Duct Obstruction, Extrahepatic →
Sponsor
Gangnam Severance Hospital
Who can join
19 and older, any sex, with Bile Duct Obstruction, Extrahepatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured. The aim of this study was to validate the clinical usefulness of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using biliary cancer-related protein expressed only in bile duct cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04759794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cytology staining
Trials testing the same drug.
- NCT04293497 — Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer · NA · completed
- NCT03708445 — Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer · NA · completed
Other Gangnam Severance Hospital trials
Trials by the same sponsor.
- NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
- NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
- NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
- NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
- NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04759794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04759794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing